We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
As biomedical innovation has developed advanced therapeutic modalities and prospective cures for ailments that previously had no comparable courses of treatment, the challenge of crafting sustainable reimbursement models has inspired a variety of value-based agreements. Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy’s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers’ expectations for future models of reimbursing treatments based on outcomes versus delivery.
Moderator: Yasmeen Rahimi, Managing Director and Senior Research Analyst Biotechnology, ROTH Capital Partners